

GENETICS AND GENOMICS IN CLINICAL RESEARCH COURSE

Copy Number Variations (CNVs)

October 1st 2013


Fady M. Mikhail, MD, PhD

Associate Professor

Department of Genetics

Copy number variations (CNVs)


- Stretches of genomic DNA present in more than or less than two copies that can range in size from kilobases (kb) to megabases (Mb)
- Cannot be identified by G-banded chromosome analysis, but can be identified by cytogenomic array methodologies and whole genome sequencing
- Can be germline or somatic
- Can be inherited or sporadic (*de novo*). Large *de novo* CNVs are more likely to be disease causative



Copy number variations (CNVs) (cont'd)

- Recent studies have indicated that CNVs are widespread in the human genome and are a significant source of human genetic variation accounting for population diversity and human disease. Between any two individuals the number of base-pair differences due to CNVs is >100-fold higher compared with SNPs
- The phenotypic effects of CNVs are sometimes unclear and depend on whether they span dosage-sensitive genes or regulatory sequences
- In a clinical setting, CNVs have been categorized into five groups (according ACMG practice guidelines):
 1. Benign
 2. Variant of unknown significance (VOUS) - most likely benign
 3. VOUS - uncertain significance
 4. VOUS - most likely pathogenic
 5. Pathogenic

Size and frequency of major categories of genetic variants




Genomic rearrangements versus base pair alterations

| | Genomic rearrangements (including CNVs) | Base pair (bp) alterations |
|--|---|--|
| Size | Thousands to millions of bp | Small scale gene mutations (e.g. point mutations) |
| Gene content | One to several genes | One gene |
| Molecular mechanism | <ul style="list-style-type: none"> • Mechanisms mediated or stimulated by genomic architecture <u>OR</u> • Exogenous factors (e.g. ionizing radiation) | <ul style="list-style-type: none"> • Errors of DNA replication and/or repair <u>OR</u> • Exogenous factors (e.g. chemical mutagens) |
| Locus-specific mutation rate (μ) | <u>CNVs:</u> 1.7×10^{-6} - 1.2×10^{-4} | <u>Single-nucleotide changes:</u> 1.8 - 2.5×10^{-8} |
| Method of detection | <ul style="list-style-type: none"> • G-banded chromosomes • FISH • Cytogenomic arrays | <ul style="list-style-type: none"> • DNA sequencing • Other molecular techniques |

Benign CNVs


- A recent estimate of the proportion of the human genome that is structurally variant (i.e. benign CNVs) is in the order of ~5-10%
- The majority (>95%) of benign CNVs in humans are <100 kb in size



Can CNVs cause disease?

- Most CNVs are benign variants that will not directly cause disease
- CNVs that affect critical developmental genes can cause disease
- Recent reviews have listed 17 conditions of the nervous system alone – including Parkinson's Disease and Alzheimer's Disease – that can result from copy number variation
- Genes that are involved in the immune system and in brain development and activity – two functions that have evolved rapidly in humans – tend to be enriched in CNVs

Molecular mechanisms by which genomic rearrangements can convey phenotypes



Interpretation of the clinical significance of CNVs

Table 1. Assessment of Pathogenicity of a CNV^a


| Primary Criteria | Indicates CNV Is Probably | |
|---|---------------------------|--------|
| | Pathogenic | Benign |
| 1. a. Identical CNV inherited from a healthy parent ^b | | ✓ |
| b. Expanded or altered CNV inherited from a parent | ✓ | |
| c. Identical CNV inherited from an affected parent | ✓ | |
| 2. a. Similar to a CNV in a healthy relative | | ✓ |
| b. Similar to a CNV in an affected relative | ✓ | |
| 3. CNV is completely contained within genomic imbalance defined by a high-resolution technology in a CNV database of healthy individuals | | ✓ |
| 4. CNV overlaps a genomic imbalance defined by a high-resolution technology in a CNV database for patients with ID/DD, ASD, or MCA | ✓ | |
| 5. CNV overlaps genomic coordinates for a known genomic-imbalance syndrome (i.e., previously published or well-recognized deletion or duplication syndrome) | ✓ | |
| 6. CNV contains morbid OMIM genes ^c | ✓ | |
| 7. a. CNV is gene rich | ✓ | |
| b. CNV is gene poor | | ✓ |

Table 1. Assessment of Pathogenicity of a CNV^a


| | Indicates CNV Is Probably | |
|--|---------------------------|--------|
| | Pathogenic | Benign |
| General Findings^d | | |
| 1. a. CNV is a deletion | ✓ | |
| b. CNV is a homozygous deletion | ✓ | |
| 2. a. CNV is a duplication (no known dosage-sensitive genes) | | ✓ |
| b. CNV is an amplification (greater than 1 copy gain) | ✓ | |
| 3. CNV is devoid of known regulatory elements | | ✓ |

Miller DT et al. Am J Hum Genet 2010;86:749-64

CNV burden across various neurodevelopmental phenotypes




Variable expressivity of hotspot CNVs



The frequency of CNV deletions and reciprocal duplications for six genomic hotspots associated with neurological disease are shown (ID/DD, autism, epilepsy, schizophrenia, and bipolar disorders).









Array Comparative Genomic Hybridization (array CGH)




Cytogenomic array methodologies

| Array CGH | SNP arrays |
|---|---|
| Single-sequence oligonucleotides of ~60 bp | Two 20–60 bp oligonucleotides of different sequence |
| Two labeled DNAs (patient and control) per hybridization | Only patient DNA labeled and hybridized |
| Resolution down to size of oligonucleotides; exon by exon | Resolution limited by SNP distribution |
| No detection of UPD or consanguinity | Able to detect consanguinity and most UPD |
| Limited SNP addition possible recently | Detection of most known clinically relevant CNVs but not exon by exon |

Agilent 8x60k array



Agilent 8x60k array – subarray 2_1



CNV Databases

- Database of Genomic Variants: <http://projects.tcag.ca>
- UCSC Genome Browser: <http://www.genome.ucsc.edu/cgi-bin/hgGateway>
- Ensembl Database: http://useast.ensembl.org/Homo_sapiens/Info/Index
- NCBI Map Viewer: <http://www.ncbi.nlm.nih.gov/projects/mapview/>
- DECIPHER Database: <http://decipher.sanger.ac.uk/>
- ISCA Consortium: <https://www.iscaconsortium.org/>

Conclusions

- CNVs are widespread in the human genome and are a significant source of human genetic variation accounting for population diversity and human disease
- High-resolution cytogenomic array is a powerful and efficient method (in both clinical and research settings) for detecting pathogenic CNVs in patients with DD, ID, ASD, and MCAs
- Clinical high-resolution cytogenomic array has proven to have an ~15-20% overall detection rate of genomic rearrangements in these patients
- A specific genetic diagnosis in these cases facilitates comprehensive medical care and accurate recurrence risk counseling for the family